Peptide Therapy — Virginia Beach & Blacksburg, VA
Peptides Work. Most Clinics Have No Idea Which Ones — Or Why.
Most hormone, wellness clinic and gyms now offer peptide therapy. Walk into any of them and you will leave with Sermorelin or PT-141 — because those are the two peptides on the menu. Your biology had nothing to do with it.
The problem is not the peptides — it is the absence of clinical logic connecting your biology to the compound.
At The Johnson Center, no peptide protocol begins without a complete picture of your cellular function. The GH axis. Mitochondrial efficiency. Inflammatory load. Gut integrity. Cognitive signaling. We identify where the communication failures are — and then we select the peptides that address those specific failures. In sequence. With monitoring. From pharmacies we trust.
Dr. Barbara Johnson, MD — 30+ years clinical medicine, surgical background, functional medicine, fellowship in cellular medicine and certification in peptides. Serving Virginia Beach, Blacksburg, and telemedicine patients across Virginia and North Carolina.
THE CORE PROBLEM
Peptide therapy is one of the most powerful tools in precision medicine. It is also one of the most misused.
Not because practitioners are careless, but because prescribing peptides without a diagnostic framework is essentially guessing.
THE PROBLEM
Why Most Peptide Therapy Underdelivers
A menu is not a protocol.
The peptide market has a structural problem. Practices list peptides the way a restaurant lists specials. You describe your symptoms. They match a peptide to the symptom. You leave with an injection kit and a vague promise about energy and recovery.
The problem isn't the peptides. Peptides are extraordinary molecules. The problem is the absence of clinical logic connecting your biology to the compound you're injecting.
Consider what determines whether Sermorelin will actually work for you: your baseline IGF-1, the integrity of your pituitary GH release pattern, whether your cortisol rhythm is blunted in a way that suppresses GH secretion regardless of stimulation, whether mitochondrial insufficiency is limiting downstream utilization of any GH increase you produce. A clinic that checks your testosterone and prescribes Sermorelin is skipping the entire diagnostic chain that determines whether that peptide will produce a clinical result.
This is why patients arrive at our practice having tried peptide therapy elsewhere with partial results or none at all. The peptide wasn't wrong. The diagnostic foundation wasn't there.
The Principle
A peptide is a cellular messenger. It carries a specific instruction to a specific receptor system. If the cellular environment receiving that message is compromised — by mitochondrial dysfunction, inflammatory overload, HPA dysregulation, or nutrient depletion — the message degrades before it arrives. Fixing the messenger without fixing the environment is incomplete medicine.
THE DIAGNOSING PROTOCOL
How We Select Peptides — Not From a Menu
Before a single peptide is prescribed, we run a comprehensive cellular assessment. This is what separates a protocol from a menu. We are looking for four things:
01
02
03
04
Where is cellular energy failing?
The Organic Acids Test maps mitochondrial efficiency, Krebs cycle function, neurotransmitter metabolism, and oxidative stress markers. This tells us whether the cell itself has the energy substrate to respond to peptide signaling — and which metabolic pathways are most compromised. This is the foundation of everything that follows.
Which hormonal axes are disrupted?
The GH/IGF-1 axis governs the primary GH secretagogue peptides (Sermorelin, Tesamorelin). The HPA axis governs cortisol rhythm, which directly affects GH release patterns and peptide receptor sensitivity. Sex hormones affect tissue repair signaling. We map all axes before recommending anything that touches hormonal biology.
What is the inflammatory and gut integrity picture?
Systemic inflammation degrades hormone receptor sensitivity, suppresses mitochondrial function, and accelerates cellular aging. For patients whose primary presentation is fatigue, brain fog, or hormone resistance, gut permeability is frequently the upstream problem. We assess inflammatory markers, gut permeability directly via Larazotide-relevant markers, and intestinal integrity before deploying gut or repair peptides.logy.
What is the cognitive and neurological picture?
Cognitive peptides like Dihexa and PE-22-28 are considered in the context of neurotransmitter and BDNF data from the OAT, the HPA pattern (cortisol suppresses cognitive function directly), and the clinical cognitive presentation. We do not prescribe cognitive peptides as a first-line intervention — most cognitive symptoms in our population are downstream effects of fixable upstream problems.
The Sequence
Cellular energy support comes first. Then hormonal stabilization. Then targeted peptide deployment. Peptides amplify a functional system — they do not build one. The sequence is critical for peptide therapy to be effective.
THE PEPTIDES WE PRESCRIBE IN VIRGINIA BEACH & BLACKSBURG
We Organize by Biological System — Not by Symptom
We currently prescribe ten peptides across five categories as these are the only ones currently available through an FDA approved compound pharmacy. Selection for any individual patient is based entirely on diagnostic findings.
Growth Hormone Axis. Sermorelin & Tesamorelin Both are growth hormone-releasing hormone (GHRH) analogs that stimulate your pituitary gland to produce and release its own growth hormone — rather than introducing exogenous GH. The distinction matters clinically: physiological GH release is pulsatile, regulated, and self-limiting. These compounds preserve that regulation. Sermorelin The most widely studied GHRH analog with the longest safety record. It is short-acting, producing a natural GH pulse that mimics physiological release. Appropriate for patients who need gradual GH axis restoration with careful HPA monitoring. Tesamorelin A stabilized GHRH analog with demonstrated efficacy for visceral adiposity reduction in addition to GH axis restoration. It produces more sustained GH elevation than Sermorelin and is particularly indicated in patients with significant body composition changes, metabolic inflexibility, or the age-related GH axis decline pattern. Protocol selection is based on your diagnostic picture — not on which compound is easier to prescribe. Diagnostic Indicators Low IGF-1, IGFBP-3 below optimal range, clinical pattern of GH-axis decline — poor sleep quality, inability to build or maintain muscle, slow recovery, increased visceral fat, reduced vitality.
Mitochondria & Metabolic SS-31 and 5-Amino 1MQ This is the category that most practices in Hampton Roads — and most functional medicine practices nationally — are not yet working with clinically. Both compounds target cellular energy production at the level of the mitochondria. They are not GH peptides. They operate on a different and more fundamental biological layer. SS-31 (Elamipretide) Targets the inner mitochondrial membrane, reducing reactive oxygen species (ROS) production and improving electron transport chain efficiency. Mitochondrial ROS is one of the primary drivers of cellular aging. When the electron transport chain is inefficient — under chronic stress, inflammatory load, nutrient depletion, and age — cells produce more waste energy than usable ATP. SS-31 directly addresses this inefficiency at its source. 5-Amino 1MQ Inhibits NNMT (nicotinamide N-methyltransferase), an enzyme that depletes NAD+ — the essential coenzyme for mitochondrial energy production. By blocking this pathway, 5-Amino 1MQ drives NAD+ levels up, restores mitochondrial function, and supports fat mobilization and metabolic flexibility. It works synergistically with SS-31 in patients whose primary presentation is cellular energy failure and metabolic dysfunction. Diagnostic Indicators CDR pattern, mitochondrial insufficiency markers, biological age acceleration, metabolic inflexibility, exercise intolerance disproportionate to fitness level, the age-44 or age-60 biological reorganization wave with multi-system symptom presentation.
Gut Integrity & Tissue Repair. Larazotide & GHK-CU Gut permeability is frequently the upstream driver behind systemic inflammation, hormone resistance, and mitochondrial suppression. These compounds address the mechanism — not the symptom. Larazotide A tight junction regulator that blocks the zonulin signaling pathway — the primary mechanism by which intestinal permeability increases. When zonulin is overactivated (by stress, infection, dietary triggers, or dysbiosis), tight junctions open and allow undigested proteins and bacterial components to cross into systemic circulation. The resulting immune activation drives systemic inflammation, hormone receptor resistance, mitochondrial suppression, and accelerated aging. Larazotide addresses the upstream mechanism rather than treating the downstream symptoms. It is precise, targeted, and often among the most impactful interventions in patients whose entire symptom picture is rooted in gut-driven inflammation. GHK-Cu (Copper Peptide) A naturally occurring copper-binding peptide that promotes collagen and elastin synthesis, stimulates wound healing, reduces oxidative damage, and modulates inflammatory tone. Its mechanism includes activation of tissue repair genes and reduction of inflammatory cytokines. In clinical use, GHK-Cu addresses tissue repair failure, skin integrity changes, and inflammatory burden — and is relevant in patients with impaired healing responses or significant oxidative stress patterns on OAT. Diagnostic Indicators Elevated inflammatory markers, gut permeability findings on OAT or dedicated GI testing, inflammatory patterns without clear infection source, impaired tissue repair, high oxidative stress burden.
Cognitive & Neurological. Dihexa & PE-22-28 Cognitive peptides are the most nuanced category and the one that requires the most complete diagnostic picture before deployment. The reason we do not use them as first-line interventions: most cognitive symptoms in our patient population are downstream effects of fixable upstream problems. HPA dysregulation suppressing prefrontal function. Mitochondrial insufficiency reducing ATP available to the brain. Gut permeability driving neuroinflammation. Addressing the upstream problem frequently resolves the cognitive symptom without cognitive-specific peptides. When it does not — that is when these compounds become appropriate. Dihexa Amplifies BDNF (brain-derived neurotrophic factor) signaling through HGF pathway activation. It supports neuroplasticity, memory consolidation, and executive function. Dihexa is among the most potent BDNF amplifiers in the current peptide armamentarium — several orders of magnitude more potent than BDNF itself by some preclinical measures. It is not appropriate as a first-line or casual intervention. PE-22-28 A synthetic analog of spadin that targets the TREK-1 potassium channel — a mechanism distinct from any traditional antidepressant or cognitive enhancer. TREK-1 modulation has demonstrated antidepressant effects in preclinical models, and PE-22-28 is emerging as a precision cognitive tool for patients with motivational failure, flat affect, or cognitive symptoms that persist despite hormonal and mitochondrial optimization. The specificity of mechanism is what makes it clinically useful — it is not a broad stimulant. Diagnostic Indicators Persistent cognitive symptoms despite upstream optimization; neurotransmitter insufficiency on OAT; HPA-driven cognitive suppression that has not resolved with cortisol normalization; executive function decline disproportionate to age.
Vitality, Joint & Sexual Health. PT-141 & Pentosan These compounds address the functional layers — sexual health and structural integrity — that persist as clinical concerns even after hormonal, mitochondrial, and inflammatory optimization. PT-141 (Bremelanotide) A melanocortin receptor agonist that addresses sexual dysfunction through a central nervous system mechanism — unlike PDE5 inhibitors that work peripherally. It acts on hypothalamic pathways involved in sexual arousal and desire, making it relevant for both women and men experiencing libido loss that is not explained by hormone deficiency alone. For patients whose sexual health symptoms persist despite hormonal optimization, PT-141 addresses a different and often overlooked layer of the system. Pentosan Polysulfate Sodium A semi-synthetic polysaccharide with both chondroprotective and anti-inflammatory properties. It is primarily used for joint and connective tissue preservation — supporting cartilage integrity, reducing joint inflammation, and protecting against enzymatic degradation of the joint matrix. For high-performing patients with joint-loading demands or early degenerative changes, Pentosan addresses the structural maintenance layer that GH peptides and mitochondrial compounds do not directly reach. Diagnostic Indicators PT-141: Persistent libido dysfunction despite hormonal optimization; CNS-mediated sexual health complaints; history of failed response to hormonal interventions alone. Pentosan: Joint pain, early cartilage degeneration, high-load athletic or occupational demands, inflammatory joint pattern.
REGULATORY CONTEXT
The 2026 FDA Peptide Reclassification — What It Actually Means
On February 27, 2026, HHS Secretary Kennedy announced that approximately 14 peptides previously restricted under the FDA's Category 2 list would be reclassified to Category 1 — restoring legal access through licensed compounding pharmacies under a physician's prescription.
What this means in practice: compounds that had been pushed into regulatory gray areas — and in many cases into unregulated gray-market sourcing — are being returned to the regulated physician-prescribed, pharmacy-compounded pathway where they belong.
Category 1 compounds can be legally compounded by a licensed pharmacy under a physician's prescription. This is the standard pathway for compounded medications in the United States — the same pathway used for bioidentical hormones, custom-dose thyroid medications, and other compounded pharmaceuticals.
Category 2 compounds were flagged by the FDA as requiring additional evaluation before compounding could continue. During the restriction period, some practices suspended these protocols entirely. Others directed patients to unregulated sources. The reclassification restores the regulated pathway.
The peptides The Johnson Center currently prescribes were not affected by the prior restriction period in terms of our clinical protocols. What the reclassification changes is the regulatory landscape for additional compounds that we are now preparing to add to our formulary — compounds like CJC-1295, Ipamorelin, BPC-157, and Thymosin Alpha-1 that have strong clinical evidence and that our patients have been asking about.
The sourcing standard and clinical oversight framework at The Johnson Center have not changed. We prescribe exclusively through FDA-registered compounding pharmacies meeting USP 797 and 795 standards. The reclassification expands what we can prescribe through that framework — it does not change the framework itself.
PEPTIDE SOURCING STANDARDS
Why Sourcing Is Not a Minor Detail
The 2023 FDA restrictions on certain compounded peptides created an unintended consequence: patients who had been receiving these compounds through legitimate physician-pharmacy channels were suddenly cut off. Many turned to the only sources still available — online vendors selling peptides labeled "for research use only" and informal distribution through fitness and wellness networks.
These sources are not held to pharmaceutical or compounding pharmacy quality standards. The risks they introduce are separate from whatever the peptide itself does — they are manufacturing and quality risks with real clinical consequences:
Unregulated Sourcing Risks
Endotoxin contamination — bacterial byproducts that trigger systemic inflammatory response when injected
Heavy metal content — arsenic, lead, mercury at levels that would fail pharmaceutical testing
Residual solvents from manufacturing — organic compounds that are toxic at injection-relevant doses
Microbial contamination — bacteria, fungi, or viral particles that bypass the immune system when injected subcutaneously
Peptide concentration mismatch — the stated dose on the label does not match the actual peptide content in the vial
The 2026 reclassification is intended to close this gap — restoring access to properly regulated, physician-prescribed, pharmacy-compounded peptides. But the reclassification does not retroactively make a gray-market peptide safe. If you are currently using peptides from a non-prescription source, the compound itself may be legitimate. The question is whether the manufacturing, testing, and quality control behind that specific vial meets the standard you would expect for something you are injecting into your body.
Our Sourcing Standards
The Johnson Center prescribes exclusively through FDA-registered compounding pharmacies that meet USP 797 (sterile compounding) and USP 795 (non-sterile compounding) standards.
Every compound is third-party tested for potency, sterility, endotoxins, and particulate matter. We discuss sourcing openly with every patient — because if you are going to inject a peptide, you should know exactly where it came from and what quality controls it passed.
PHYSICIAN LEAD PEPTIDE THERAPY
Why Physician-Led Peptide Therapy Matters
Most peptide therapy is delivered by practitioners who are not physicians, or through online telehealth platforms with minimal oversight. This matters for two reasons.
Reason 1: Peptides interact with complex biological systems.
GH secretagogues affect the HPA axis. PT-141 acts on hypothalamic melanocortin receptors. Dihexa amplifies BDNF signaling at a potency level that requires understanding the downstream effects. Larazotide modulates tight junction permeability with systemic inflammatory implications. A provider who does not have the diagnostic depth to evaluate these systems before prescribing is operating without a complete picture of potential interactions.
This is not a safety indictment of every practitioner in the market. It is a statement about diagnostic infrastructure. At The Johnson Center, every peptide protocol is designed by a physician with 30+ years of clinical experience, including a surgical background, specialized cellular medicine fellowship, and peptide certification in which understanding systemic interactions was not optional.
Reason 2: The protocol is the treatment — not the peptide.
Peptides do not work in isolation. The clinical outcome depends on what you are combining them with, what you are addressing at the same time, and in what sequence. A GH secretagogue prescribed without addressing the cortisol rhythm that is suppressing GH release will underperform. Larazotide prescribed without addressing the upstream dysbiosis driving zonulin activation treats the permeability without solving the cause. PE-22-28 prescribed for brain fog before the HPA and mitochondrial picture has been assessed may be treating a symptom whose root is two steps upstream. Designing a complete protocol — not just selecting a compound — requires a physician who has built the diagnostic picture comprehensively.
Dr. Barbara Johnson
I did not add peptide therapy to my practice because it became trendy. I incorporated it because the research on mitochondrial peptides, GH axis restoration, gut integrity compounds, and cognitive signaling maps directly onto the cellular energy framework I have built my clinical approach around. These are not add-ons. In a correctly sequenced protocol, they are force multipliers for everything else we are doing.
IS PEPTIDE THERAPY FOR YOU
Peptide Therapy at The Johnson Center May Be Appropriate If:
We see patients at our Virginia Beach and Blacksburg locations. Telemedicine follow-up is available throughout Virginia and North Carolina.
You have tried peptides elsewhere and felt partial improvement — or nothing — and want to understand why
You are in your 40s or 50s and experiencing declining energy, recovery, cognitive sharpness, or body composition that does not respond to lifestyle optimization
You have been told your labs are normal but your performance and vitality are clearly not
You are a high-performing executive or athlete who needs your cellular machinery to work at a level that supports the demands you place on it
You have a complex clinical picture — hormone dysregulation, fatigue, gut issues, cognitive symptoms — and you want a protocol that addresses all of it as a system
You want to understand the mechanism behind what you are taking, not just be handed a vial and a dosing schedule
You are currently purchasing peptides from a non-prescription source and want to transition to a physician-supervised, pharmacy-grade protocol
You are a man in your late 40s or 50s experiencing declining testosterone, recovery failure, or body composition changes and want to know whether peptide therapy belongs in your protocol
You are focused on longevity and optimizing your mental and physical well-being — not managing disease, but building the biological foundation that keeps you performing at the highest level for the longest time possible."
Peptide Therapy That Starts With Your Biology — Not a Menu.
Comprehensive cellular assessment. Physician-designed protocol. Ten peptides across five categories, sourced from licensed compounding pharmacies, deployed in sequence, based on your diagnostic picture.
VIRGINIA BEACH | BLACKSBURG | TELEMEDICINE ACROSS VIRGINIA AND NORTH CAROLINA
GLP-1 + Sermorelin: The Combination We Reach For More Than Any Other
First: GLP-1s Are Peptides
Semaglutide and tirzepatide — the compounds behind Ozempic, Wegovy, and Mounjaro — are peptides. GLP-1 (glucagon-like peptide-1) is a naturally occurring signaling molecule. The medications are synthetic analogs of it. This matters because it means GLP-1 therapy already fits within the same biological framework as everything else on this page: targeted molecular signaling, receptor-specific action, cellular mechanism. The difference is that GLP-1 agonists are FDA-approved drugs rather than compounded peptides — but the underlying science is the same category.
The clinical problem GLP-1 therapy creates — and why it matters
GLP-1 agonists are highly effective for weight loss and metabolic regulation. They are also, in a meaningful subset of patients, muscle-loss accelerators. Rapid caloric reduction — which is exactly what these medications produce — can drive the body to catabolize lean muscle tissue alongside fat. For patients who begin a GLP-1 protocol already carrying less muscle than is optimal for their age and metabolic demands, this is a significant clinical problem.
Muscle tissue is not simply cosmetic. It is metabolically active — it is one of the primary sites of glucose disposal, a driver of resting metabolic rate, and a direct determinant of long-term metabolic resilience. Patients who lose substantial muscle mass during GLP-1 therapy frequently find that weight regain, if it occurs, is disproportionately fat — a worse metabolic starting point than before they began.
Standard guidance is to increase resistance exercise during GLP-1 therapy. That guidance is correct. It is also insufficient for a specific subset of patients: those who begin the program with low baseline muscle mass and whose musculoskeletal capacity — whether from injury, deconditioning, fatigue, or age-related GH axis decline — limits their ability to build muscle through exercise alone. For these patients, exercise prescription is necessary but not sufficient.
What Sermorelin adds to the equation
Sermorelin stimulates the pituitary gland to produce and release its own growth hormone in a physiological, pulsatile pattern. GH is the primary driver of muscle protein synthesis, lean tissue preservation, and fat mobilization at the cellular level. In patients whose GH axis has declined — which is the majority of patients in their 40s and 50s — GH secretion is insufficient to protect lean mass under caloric restriction, regardless of exercise.
Adding Sermorelin to a GLP-1 protocol does not override the weight loss effect. It supports the biological conditions under which the body preferentially loses fat rather than muscle during that caloric deficit. The result, in appropriate patients, is a better body composition trajectory — more fat lost, less muscle sacrificed — and a stronger metabolic foundation coming out of the weight loss phase.
Who This Combination is For - and Who It Isn't
We do not start every GLP-1 patient on Sermorelin. This combination is specifically indicated for patients who begin the program with lower-than-optimal muscle mass and who cannot meaningfully build muscle through exercise — due to fatigue, injury, recovery failure, or a GH axis decline pattern that limits anabolic response. For patients with adequate muscle mass and robust exercise capacity, resistance training under a GLP-1 protocol is often sufficient. The diagnostic picture — IGF-1, IGFBP-3, body composition analysis, and clinical exercise response — determines the recommendation. This is not a default add-on. It is a precision intervention for a specific metabolic profile.
Why this combination is underused
Most GLP-1 prescribers are not peptide prescribers. The two therapeutic categories rarely exist in the same clinical practice, which means the problem of muscle loss on GLP-1 therapy is frequently identified but inadequately addressed. Patients are told to exercise more. Some are referred to dietitians. Very few are evaluated for GH axis status or offered a protocol that addresses the hormonal biology underlying their anabolic limitation.
At The Johnson Center, GLP-1 therapy and peptide therapy exist within the same diagnostic and clinical framework. If you are on — or considering — a GLP-1 protocol and you have concerns about muscle preservation, body composition, or your ability to build lean mass through exercise, that is a conversation worth having before you begin, not after you have lost muscle you cannot easily rebuild.
Learn more about our
What's Coming as the FDA Completes Reclassification
On February 27, 2026, HHS Secretary Kennedy announced that approximately 14 peptides previously restricted under the FDA's Category 2 list would be restored to legal compounding status. The formal updated guidance is expected within weeks of that announcement.
We are listing these here for one reason: transparency. Patients who have been accessing these compounds through unregulated sources deserve to know that a physician-supervised, pharmacy-grade option is coming. The reclassification does not make a gray-market peptide retroactively safe — but it does restore the regulated pathway that should have been available all along.
Growth Hormone Axis
CJC-1295
A long-acting GHRH analog with a significantly extended half-life compared to Sermorelin. Produces sustained GH elevation rather than a discrete pulse — expanding the GH axis protocol options for patients who need more continuous stimulation. Will be combined with Ipamorelin for patients whose diagnostic picture calls for enhanced GH release with cortisol and prolactin sparing.
Ipamorelin
A selective GH secretagogue that stimulates GH release without significantly raising cortisol or prolactin — the cleanest GH pulse stimulator in the category. Particularly appropriate for HPA-sensitive patients where cortisol elevation is a clinical concern. Will be used as a standalone and in CJC-1295/Ipamorelin combined protocols.
Tissue Repair & Gut Healing
BPC-157
Body Protection Compound-157 — a pentadecapeptide derived from human gastric juice with one of the broadest biological action profiles in the peptide category. Promotes angiogenesis, accelerates tissue repair, reduces systemic inflammation, protects gut lining integrity, and supports the blood-brain barrier. Over 180 PubMed citations. With Larazotide already in our formulary addressing tight junction regulation, BPC-157 adds mucosal healing and systemic repair capacity to the gut integrity protocol.
TB-500 (Thymosin Beta-4)
A tissue repair peptide that supports cell migration and healing through actin regulation, anti-inflammatory signaling, and promotion of new cell growth. Works synergistically with BPC-157 in musculoskeletal and systemic repair protocols. Directly relevant for high-performing patients with injury history, recovery failure, or significant connective tissue demands.
KPV
A tripeptide (Lys-Pro-Val) derived from alpha-MSH with potent anti-inflammatory and gut mucosal protective properties. Acts directly on intestinal epithelial cells and immune cells to reduce inflammatory cytokine production. In patients with IBD-adjacent presentations, significant mucosal inflammation, or systemic inflammatory burden with a clear gut origin, KPV addresses a layer that Larazotide (tight junction regulation) and BPC-157 (mucosal repair) do not fully cover.
Mitochondria & Metabolic
MOTS-C
A mitochondrial-derived peptide encoded in the mitochondrial genome that activates AMPK — the master metabolic regulator — and stimulates mitochondrial biogenesis. Adding MOTS-C to our existing SS-31 and 5-Amino 1MQ protocols creates a three-compound mitochondrial tier that addresses ROS reduction (SS-31), NAD+ restoration (5-Amino 1MQ), and mitochondrial biogenesis (MOTS-C). No practice in Virginia Beach is working at this level of mitochondrial specificity.
AOD-9604
A fragment of the GH molecule that retains the fat metabolism effects of growth hormone without the growth-promoting or insulin-sensitizing effects of full GH. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat storage) through a beta-3 adrenergic receptor mechanism. Relevant for patients with persistent visceral adiposity or metabolic inflexibility who are already on GH axis protocols and need targeted metabolic support.
Immune Modulation
Thymosin Alpha-1
A thymic peptide with over 200 published studies since 2021, many driven by renewed research interest following COVID-19. Enhances T-cell maturation and function, supports immune surveillance, and modulates inflammatory tone without overstimulating immune response — a critical distinction for patients with autoimmune-adjacent presentations or chronic inflammatory burden. For patients presenting with post-viral fatigue, recurrent illness, or elevated inflammatory markers without clear infectious source, Thymosin Alpha-1 addresses a biological layer that no compound in our current formulary reaches.
Cognitive & Neurological
Semax
A synthetic analog of ACTH that modulates dopaminergic and serotonergic systems and has been studied for cognitive enhancement, neuroprotection, and anxiety reduction. Works through a mechanism distinct from PE-22-28 — primarily via BDNF upregulation and monoamine modulation. Adding Semax to the cognitive category gives us two mechanistically different tools for patients with complex neurological presentations.
Selank
A synthetic analog of tuftsin with anxiolytic, nootropic, and immune-modulatory properties. Unlike conventional anxiolytics, Selank does not produce sedation, dependence, or tolerance. It modulates the GABAergic system and has demonstrated effects on memory consolidation, stress response regulation, and HPA axis normalization. For patients whose cognitive symptoms are significantly anxiety-driven or whose HPA dysregulation has not fully normalized with cortisol-targeted protocols, Selank provides a precision tool that bridges the cognitive and immune categories.
When These Become Available
We will update this page and notify established patients when the formal FDA guidance is published and our pharmacy partners confirm compliant supply. If you are currently accessing any of these compounds through non-prescription sources, we encourage you to schedule a consultation now — so that when the regulated pathway opens, your protocol is already built on a complete diagnostic picture rather than starting from zero.